PT  - JOURNAL ARTICLE
AU  - Elitzur, Moshe
AU  - Kaplan, Scott
AU  - Ivezić, Željko
AU  - Zilberman, David
TI  - The impact of policy timing on the spread of COVID-19
AID  - 10.1101/2021.03.16.21253764
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.16.21253764
4099  - http://medrxiv.org/content/early/2021/03/23/2021.03.16.21253764.short
4100  - http://medrxiv.org/content/early/2021/03/23/2021.03.16.21253764.full
AB  - We model COVID-19 data for 89 nations and US states with a recently developed formalism that describes mathematically any pattern of growth with the minimum number of parameters. The results show that the disease has a typical duration of 18 days, with a significant increase in fatality when it lasts longer than about 4 months. Searching for correlations between “flattening of the curve” and preventive public policies, we find strong statistical evidence for the impact of the first implemented policy on decreasing the pandemic growth rate; a delay of one week in implementation nearly triples the size of the infected population, on average. Without any government action, the initial outburst still slows down after 36 days, possibly thanks to changes in public behavior in response to the pandemic toll. Stay-at-home (lockdown) was not the first policy of any sample member and we do not find statistically meaningful evidence for its added impact, similar to a recent study that employed an entirely different approach. However, lockdown was mostly imposed only shortly before the exponential rise was arrested. The possibility remains that lockdown might have shortened significantly the initial exponential rise had it been employed as first, rather than last resort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTwo of the authors (SK and DZ) received support from IGI and NSF CBET (Grant no. 2030362)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearch based on public data. All data sources are referenced in the article. https://github.com/CSSEGISandData/COVID-19 https://github.com/nytimes/covid-19-data